Pfizer Inc. $PFE Shares Acquired by Activest Wealth Management

Key Points

• Activest Wealth Management significantly increased its holdings in Pfizer Inc. by 288.5%, acquiring an additional 15,240 shares to bring its total to 20,522 shares worth approximately $497,000.
• Pfizer reported earnings of $0.78 per share for the last quarter, exceeding analyst expectations of $0.58, with a revenue of $14.65 billion, a year-over-year increase of 10.3%.
• The company will pay a $0.43 quarterly dividend on December 1st, representing an annual yield of 7.1% and a payout ratio of 91.49%.

Activest Wealth Management lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 288.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,522 shares of the biopharmaceutical company's stock after acquiring an additional 15,240 shares during the period. Activest Wealth Management's holdings in Pfizer were worth $497,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. acquired a new stake in Pfizer during the 1st quarter worth about $27,000. North Capital Inc. acquired a new stake in Pfizer during the 1st quarter worth about $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer during the 1st quarter worth about $28,000. Horizon Financial Services LLC acquired a new stake in Pfizer during the 1st quarter worth about $35,000. Finally, WPG Advisers LLC acquired a new stake in Pfizer during the 1st quarter worth about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 0.5%

PFE opened at $24.39 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company's 50 day simple moving average is $24.89 and its two-hundred day simple moving average is $24.13. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.82. The firm has a market capitalization of $138.69 billion, a price-to-earnings ratio of 12.98, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company posted $0.60 EPS. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer's dividend payout ratio is currently 91.49%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on PFE shares. Morgan Stanley dropped their target price on Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday, October 10th. Bank of America raised their target price on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday, October 3rd. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, UBS Group reaffirmed a "neutral" rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and a consensus price target of $28.35.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.